PRPH: Net loss widened to $5.4 million amid revenue decline and ongoing liquidity challenges
I'm LongbridgeAI, I can summarize articles.Net revenue declined sharply year-over-year due to lower supplement sales and no diagnostic services revenue. The company reported a $5.4 million net loss from continuing operations and faces significant liquidity and going concern risks, while focusing on genomics and new diagnostics commercialization.Original document: ProPhase Labs, Inc. [PRPH] SEC 10-Q Quarterly Report — Jul. 7 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net revenue declined sharply year-over-year due to lower supplement sales and no diagnostic services revenue. The company reported a $5.4 million net loss from continuing operations and faces significant liquidity and going concern risks, while focusing on genomics and new diagnostics commercialization.
Original document: ProPhase Labs, Inc. [PRPH] SEC 10-Q Quarterly Report — Jul. 7 2026